Anthony Tang, ACC 2021: Findings from the RAFT-AF Trial
It was a great pleasure to meet with Anthony Tang to discuss the RAFT-AF trial results investigating the safety and efficacy of catheter ablation-based rhythm control compared with rate control for the treatment of patients with atrial fibrillation and heart failure, presented at ACC 2021.
Abstract Title: A Randomized Ablation-based atrial Fibrillation rhythm control versus rate control Trial in patients with heart failure and high burden Atrial Fibrillation – RAFT-AF
- What were the aims and design of the RAFT study? (0:19)
- What were the key inclusion criteria of the study? (0:44)
- Could you tell us a little about the study findings in terms of primary and secondary outcomes, and the reasons for early termination of the study? (1:44)
- How did these findings compare with other studies comparing rhythm-control and rate-control strategies among patients with atrial fibrillation and heart failure? (5:58)
- What are the implications of these findings for the management of patients with atrial fibrillation and heart failure, and what future studies are needed? (7:50)
Speaker disclosures: Anthony Tang has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed during a remote video call with Professor Anthony Tang as a highlight of ACC 2021, May 2021.
Share this Video
Related Videos In Heart Failure
Gregg Stone, ACC 2023: COAPT trial results – Transcatheter edge-to-edge repair with MitraClip device for functional mitral regurgitation in heart failure
The COAPT trial investigated the use of the MitraClip a novel device for patients with secondary mitral regurgitation, a condition in which blood leaks backward through the mitral valve into the left atrium of the heart. In this touchCARDIO interview Dr Gregg Stone (Mount Sinai Heart Health System, New York City, NY, USA) discusses the […]
John Boehmer, ACC 2023: MicrocorTM device for heart failure management, the BMAD trial
The BMAD trial investigated patients with heart failure assessed the use of the Microcor device on readmission rates. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, USA) to discuss purpose, findings and clinical implications of the BMAD trial in […]
John Boehmer, ACC 2023: The MicrocorTM device, monitoring tool for heart failure
The most common cause of hospital admission due to heart failure is due to excess fluid retention. The MicrocorTM device monitors fluid levels in the lungs to aid in patient management. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!